355 related articles for article (PubMed ID: 27103598)
41. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
Narotsky DL; Castano A; Weinsaft JW; Bokhari S; Maurer MS
Can J Cardiol; 2016 Sep; 32(9):1166.e1-1166.e10. PubMed ID: 27568874
[TBL] [Abstract][Full Text] [Related]
42. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
43. Unexplained cardiac failure leading to the identification of a Belgian family affected by hereditary amyloidosis.
De Pasqual A; Biessaux Y; Blettard N; Crémers S; Caers J
Acta Clin Belg; 2013; 68(4):303-5. PubMed ID: 24455802
[TBL] [Abstract][Full Text] [Related]
44. Unmasking Early Wild-Type Transthyretin Amyloidosis Cardiomyopathy in a Patient With Refractory Atrial Fibrillation and Unremarkable Cardiac Imaging.
Varedi D; Kovacsovics T; Downs Kelly E; Abraham J; Cowley J; Barrell K; Revelo MP; Stehlik J; Drakos S; Marrouche N; Wilson B; Swanson EA; Fang J; Nativi-Nicolau J
Circ Heart Fail; 2018 Jul; 11(7):e004812. PubMed ID: 29921704
[No Abstract] [Full Text] [Related]
45. Cardiac amyloidosis: a practical approach to diagnosis and management.
Kapoor P; Thenappan T; Singh E; Kumar S; Greipp PR
Am J Med; 2011 Nov; 124(11):1006-15. PubMed ID: 22017778
[TBL] [Abstract][Full Text] [Related]
46. Tafamidis for the treatment of transthyretin amyloidosis.
Lorenzini M; Elliott PM
Future Cardiol; 2019 Mar; 15(2):53-61. PubMed ID: 30767672
[TBL] [Abstract][Full Text] [Related]
47. [Ten questions about transthyretin amyloidosis].
Giovannetti A; Accietto A; Massa P; Leone O; Guaraldi P; Saturi G; Caponetti AG; Sguazzotti M; Ponziani A; Gagliardi C; Galiè N; Cortelli P; Longhi S; Biagini E
G Ital Cardiol (Rome); 2022 Sep; 23(9):676-685. PubMed ID: 36039718
[TBL] [Abstract][Full Text] [Related]
48. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms of heart failure in transthyretin vs. light chain amyloidosis.
Binder C; Duca F; Stelzer PD; Nitsche C; Rettl R; Aschauer S; Kammerlander AA; Binder T; Agis H; Kain R; Hengstenberg C; Mascherbauer J; Bonderman D
Eur Heart J Cardiovasc Imaging; 2019 May; 20(5):512-524. PubMed ID: 30649240
[TBL] [Abstract][Full Text] [Related]
50. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
Maurer MS; Bokhari S; Damy T; Dorbala S; Drachman BM; Fontana M; Grogan M; Kristen AV; Lousada I; Nativi-Nicolau J; Cristina Quarta C; Rapezzi C; Ruberg FL; Witteles R; Merlini G
Circ Heart Fail; 2019 Sep; 12(9):e006075. PubMed ID: 31480867
[TBL] [Abstract][Full Text] [Related]
51. Understanding and recognizing cardiac amyloidosis.
McVeigh T; Tennyson C
JAAPA; 2020 Oct; 33(10):16-20. PubMed ID: 32941304
[TBL] [Abstract][Full Text] [Related]
52. A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy.
Zhang KW; Zhang R; Deych E; Stockerl-Goldstein KE; Gorcsan J; Lenihan DJ
Am Heart J; 2021 Feb; 232():137-145. PubMed ID: 33212046
[TBL] [Abstract][Full Text] [Related]
53. Indications and diagnostic yield of endomyocardial biopsies for unexplained cardiomyopathy, a single center experience.
Ramaekers J; Janssens J; Waumans L; Stessens L; Dupont M; Mullens W; Martens P
Acta Cardiol; 2020 Apr; 75(2):138-146. PubMed ID: 30650043
[No Abstract] [Full Text] [Related]
54. Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.
Ternacle J; Bodez D; Guellich A; Audureau E; Rappeneau S; Lim P; Radu C; Guendouz S; Couetil JP; Benhaiem N; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Mohty D; Deux JF; Damy T
JACC Cardiovasc Imaging; 2016 Feb; 9(2):126-38. PubMed ID: 26777222
[TBL] [Abstract][Full Text] [Related]
55. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation.
Di Nora C; Sponga S; Ferrara V; Patriarca F; Fanin R; Nalli C; Lechiancole A; Vendramin I; Livi U
J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):261-267. PubMed ID: 33633041
[TBL] [Abstract][Full Text] [Related]
56. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?
Suhr OB; Anan I; Backman C; Karlsson A; Lindqvist P; Mörner S; Waldenström A
J Intern Med; 2008 Mar; 263(3):294-301. PubMed ID: 18069997
[TBL] [Abstract][Full Text] [Related]
57. How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage.
Izumiya Y; Hayashi H; Ishikawa H; Shibata A; Yoshiyama M
Intern Med; 2021 Jan; 60(1):1-7. PubMed ID: 32713926
[TBL] [Abstract][Full Text] [Related]
58. Wild type transthyretin cardiac amyloidosis in a young individual: A case report.
Ghosh S; Khanra D; Krishna V; Thakur AK
Medicine (Baltimore); 2021 Apr; 100(17):e25462. PubMed ID: 33907095
[TBL] [Abstract][Full Text] [Related]
59. [Transthyretin amyloidosis in a cohort of old and very old patients with chronic heart failure].
Poliakova AA; Semernin EN; Sitnikova MY; Аvagyan KL; Grozov RV; Pyko SA; Krutikov AN; Davydova VG; Khmelnitskaya KA; Shavloskii MM; Korzhevskii DE; Gudkova AY
Kardiologiia; 2018 SFeb; (S2):12-18. PubMed ID: 29782249
[TBL] [Abstract][Full Text] [Related]
60. Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis.
Law S; Fontana M; Gillmore JD
Cardiol Clin; 2021 Aug; 39(3):389-402. PubMed ID: 34247752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
